Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03080883|
Recruitment Status : Active, not recruiting
First Posted : March 15, 2017
Last Update Posted : July 5, 2022
|Condition or disease||Intervention/treatment||Phase|
|Cerebral Vein Thrombosis Deep Vein Thrombosis Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm Pulmonary Embolism Splanchnic Vein Thrombosis||Drug: Apixaban||Phase 3|
I. Any episode of major bleeding including fatal bleeding or clinically relevant non-major bleeding.
I. The proportion of patients who experienced at least one such bleeding event within 6 months of beginning treatment.
II. Venous thromboembolism (VTE) recurrence including deep vein thrombosis (DVT), pulmonary embolism (PE), fatal PE, or arterial thromboembolism.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive lower dose apixaban orally (PO) twice daily (BID) for 365 days.
GROUP II: Patients receive higher dose apixaban PO BID for 365 days.
After completion of study treatment, patients are followed up for 30 days.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||370 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy|
|Actual Study Start Date :||July 14, 2017|
|Actual Primary Completion Date :||June 7, 2022|
|Estimated Study Completion Date :||May 31, 2025|
Experimental: Group I (lower dose apixaban)
Patients receive lower dose apixaban PO BID for 365 days.
Experimental: Group II (higher dose apixaban)
Patients receive higher dose apixaban PO BID for 365 days.
- Proportion of patients who experience at least one bleeding event [ Time Frame: Up to 12 months ]Patients will be analyzed according to the drug they received. The analysis of major bleeding plus clinically relevant nonmajor bleeding events will primarily focus on those events which occurred during treatment or within 7 days of treatment discontinuation. Major bleeding events observed later will be described separately. The difference in the incidences of the combined endpoint at 6 months and at 12 months between treatment arms will be estimated along with a 95% confidence interval.
- Proportion of patients who experienced at least one bleeding event [ Time Frame: Up to 6 months ]Will estimate the difference in proportion of patients who experience at least one bleeding event (i.e. the primary endpoint) within 6 months of beginning treatment across the two study arms. As with the primary analysis, a 95% confidence interval will be calculated for the difference between arms.
- Venous thromboembolism recurrence [ Time Frame: Up to 12 months ]The time to the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE) outcome will be analyzed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03080883
|Principal Investigator:||Robert D McBane||Academic and Community Cancer Research United|